These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10824692)

  • 1. The usefulness of serial changes in serum CA19-9 levels in the diagnosis of pancreatic cancer.
    Tanaka N; Okada S; Ueno H; Okusaka T; Ikeda M
    Pancreas; 2000 May; 20(4):378-81. PubMed ID: 10824692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of serum and diagnostic peritoneal lavage concentration of matrix metalloproteinase-2, matrix metalloproteinase-9, carbohydrate antigen 19-9, and carcinoembryonic antigen in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lewinski A; Lekstan A; Gajda M; Ciosek J; Mrowiec S
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
    Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
    EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
    Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
    Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.
    Talar-Wojnarowska R; Gasiorowska A; Olakowski M; Lekstan A; Lampe P; Malecka-Panas E
    Pancreatology; 2010; 10(6):689-94. PubMed ID: 21242708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of serum MUC5AC in combination with CA19-9 for the diagnosis of pancreatic cancer.
    Zhang J; Wang Y; Zhao T; Li Y; Tian L; Zhao J; Zhang J
    World J Surg Oncol; 2020 Feb; 18(1):31. PubMed ID: 32028958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of N-glycan markers that improve the performance of CA19-9 in pancreatic cancer.
    Zhao YP; Zhou PT; Ji WP; Wang H; Fang M; Wang MM; Yin YP; Jin G; Gao CF
    Clin Exp Med; 2017 Feb; 17(1):9-18. PubMed ID: 26714469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic cancer serum biomarker PC-594: Diagnostic performance and comparison to CA19-9.
    Ritchie SA; Chitou B; Zheng Q; Jayasinghe D; Jin W; Mochizuki A; Goodenowe DB
    World J Gastroenterol; 2015 Jun; 21(21):6604-12. PubMed ID: 26074698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment of serum concentration of adiponectin, leptin and serum carbohydrate antigen-19.9 in patients with pancreatic cancer and chronic pancreatitis.
    Dranka-Bojarowska D; Lekstan A; Olakowski M; Jablonska B; Lewinski A; Musialski P; Sobczyk W; Kapalka A; Lampe P
    J Physiol Pharmacol; 2015 Oct; 66(5):653-63. PubMed ID: 26579571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
    Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
    Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer.
    Liu J; Gao J; Du Y; Li Z; Ren Y; Gu J; Wang X; Gong Y; Wang W; Kong X
    Int J Cancer; 2012 Aug; 131(3):683-91. PubMed ID: 21913185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis.
    Chang MC; Chang YT; Su TC; Yang WS; Chen CL; Tien YW; Liang PC; Wei SC; Wong JM
    Pancreas; 2007 Jul; 35(1):16-21. PubMed ID: 17575540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
    Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
    J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease.
    Morris-Stiff G; Teli M; Jardine N; Puntis MC
    Hepatobiliary Pancreat Dis Int; 2009 Dec; 8(6):620-6. PubMed ID: 20007080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9.
    Forsmark CE; Lambiase L; Vogel SB
    Pancreas; 1994 Nov; 9(6):731-4. PubMed ID: 7846016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.